RT Journal Article
SR Electronic
T1 Sequencing from leftover material of stored rapid Ag Tests (Ag-RDTs): a gamechanger in genomic surveillance?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.23.22276745
DO 10.1101/2022.06.23.22276745
A1 Rector, Annabel
A1 Bloemen, Mandy
A1 Schiettekatte, Gilberte
A1 Maes, Piet
A1 Van Ranst, Marc
A1 Wollants, Elke
YR 2022
UL http://medrxiv.org/content/early/2022/06/27/2022.06.23.22276745.abstract
AB Archived lateral flow antigen-detection rapid diagnostic tests (Ag-RDTs), used in the diagnosis of COVID-19, were successfully used to extract viral nucleic acids for subsequent RT-qPCR and sequencing by Sanger or Nanopore whole genome sequencing (WGS). The method was successfully applied with different brands of SARS-CoV-2 Ag-RDTs, but also with Ag-RDTs for detection of influenza, rotavirus and adenovirus 40/41. The buffer used in the Ag-RDT had an important influence on the RNA yield from the test stripand the efficiency of subsequent sequencing. Our finding that the test strip in rapid Ag tests is suited to preserve viral genomic material, even for months at room temperature, and therefore can serve as source material for genetic characterization, could improve global coverage of genomic surveillance for SARS-CoV-2 as well as for other viruses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUZ Leuven, as national reference centre , is supported by Sciensano, which is gratefully acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our laboratory functions as the Belgian national reference center (NRC) for coronaviruses, adenoviruses and rotaviruses. The positive samples and positive Ag-RDTs used in this study were anonymized leftover materials of diagnostic samples, tested by the NRC. The use of patients residual materials by the NRC was approved by the University Hospital Leuven Ethics Committee (Belgium)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors